Avidity Biosciences, Inc.
https://www.aviditybiosciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avidity Biosciences, Inc.
Big Pharma Leads Development Of Novel Antibody-Drug Conjugates
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval
Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.
Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice